TamirBio takes health and safety very seriously and is actively evaluating how its promising broad-spectrum antiviral platform may support advances, especially during the global COVID-19 pandemic. We look forward to providing further updates on this front in the very near future.
TamirBio is a clinical stage antiviral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions. TamirBio’s first target is the human papilloma virus (HPV), the worldwide leading cause of genital warts.
Throughout 2013 and the first half of 2014, TamirBio operations were successfully restructured, including privatization of the company, to support the antiviral focus, along with attracting a strong team of experienced biotechnology professionals. The company has since successfully advanced its clinical pipeline, including completion of a randomized, controlled, double-blinded phase II study in patients with genital warts. In addition, the organization’s pre-clinical activities have documented broad-spectrum activity against all viral families along with securing independent, third party validation of antiviral properties for its leading licensing candidates.
TamirBio is managed by senior executives with extensive experience in developing therapies to market.